Journal article
Amyloid Imaging with F-18-Florbetaben in Alzheimer Disease and Other Dementias
Victor L Villemagne, Kevin Ong, Rachel S Mulligan, Gerhard Holl, Svetlana Pejoska, Gareth Jones, Graeme O'Keefe, Uwe Ackerman, Henri Tochon-Danguy, J Gordon Chan, Cornelia B Reininger, Lueder Fels, Barbara Putz, Beate Rohde, Colin L Masters, Christopher C Rowe
Journal of Nuclear Medicine | SOC NUCLEAR MEDICINE INC | Published : 2011
Abstract
UNLABELLED: Amyloid imaging with (18)F-labeled radiotracers will allow widespread use, facilitating research, diagnosis, and therapeutic development for Alzheimer disease. The purpose of the study program was to compare cortical amyloid deposition using (18)F-florbetaben and PET in controls and subjects with mild cognitive impairment (MCI), frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies (DLB), vascular dementia (VaD), Parkinson disease (PD), and Alzheimer disease (AD). METHODS: One hundred nine subjects in 3 clinical studies at Austin Health were reviewed: 32 controls, 20 subjects with MCI, and 30 patients with AD, 11 with FTLD, 7 with DLB, 5 with PD, and 4 with VaD unde..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
We thank Michael Woodward, Dr. John Merory, Dr. Peter Drysdale, Kenneth Young, Dr. Sylvia Gong, Fiona Lamb, Tanya Petts, Jessica Sagona, and Jason Bradley and the Brain Research Institute for their assistance with this study. This work was supported in part by grant 509166 of the National Health and Medical Research Council of Australia, Bayer Schering Pharma AG, the Austin Hospital Medical Research Foundation, and Neurosciences Victoria. No other potential conflict of interest relevant to this article was reported.